The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
Related posts
Exclusive data from EigenPhi reveals that sandwich attacks on Ethereum have waned
Fusaka goes live as Ethereum edges closer to ‘instant feel’ UX
Ethereum treasury trade unwinds 80% as handful of whales dominate buys
Crypto treasuries lead stock recovery after shaky start to December
Ether price analysis: Will ETH continue to decline in December?
Ethereum’s Fusaka upgrade: Scaling rollups without breaking the core
